Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
Sponsor: Kymera Therapeutics, Inc.
Summary
This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.
Official title: A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
264
Start Date
2026-06-25
Completion Date
2028-12
Last Updated
2026-10-07
Healthy Volunteers
No
Conditions
Interventions
KT-621
Oral drug
Locations (7)
Kymera Investigative Site
Miami, Florida, United States
Kymera Investigative Site
Tampa, Florida, United States
Kymera Investigative Site
Dallas, Texas, United States
Kymera Investigative Site
Berlin, Germany
Kymera Investigative Site
Poznan, Poland
Kymera Investigative Site
Kamenitz, Serbia
Kymera Investigative Site
Užice, Serbia